Literature DB >> 28315507

Polymorphisms and mutations in GSTP1, RAD51, XRCC1 and XRCC3 genes in breast cancer patients.

Mazhar Salim Al Zoubi1,2, Katia Zavaglia1, Chiara Mazanti1, Mohammad Al Hamad3, Khalid Al Batayneh2, Alaa A A Aljabali2, Generoso Bevilacqua1.   

Abstract

BACKGROUND: Genotoxic factors, including ionizing radiation and oxidative stress, are associated with genomic instability and development of breast cancer (BC). The homologous recombination DNA repair (HRR) pathway, base excision repair (BER) mechanism, and antioxidative enzymes are required as defense mechanisms against these DNA damaging agents. GSTP1, XRCC1, XRCC3 and RAD51 proteins are essential components of antioxidation, BER and HRR of DNA, respectively. Deficiencies in BER, HRR and antioxidation pathways are involved in the progression of cancer.
METHODS: Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue and blood samples of BC patients of an Italian population. Genomic DNA was also extracted from blood specimens of a control group. DNA sequencing was performed for six single-nucleotide polymorphisms (SNPs) in the GSTP1, RAD51, XRCC1 and XRCC3 genes in BC patients and the control group.
RESULTS: Two variants in the 5'-UTR of the XRCC3 (rs1799794 A/G) and RAD51 (rs1801321) genes showed a significant association with susceptibility to BC (OR = 4.125; 95% CI 1.057-16.102; p = 0.03 and OR = 2.04; 95% CI 0.4925-8.449; p = 0.007, respectively). Additionally, we reported 2 mutations in intron 7 of the XRCC3 gene, CTdel (rs543072564) and A/G (rs369703243).
CONCLUSIONS: Our results underscored the existence of an association between XRCC3-5'-UTR-A/G (rs1799794) and RAD51-5'-UTR G172T (rs1801321) genotypes and BC risk in an Italian population. The presence of mutations in the intronic region of the XRCC3 gene highlights the importance of more sequence screening of DNA repair genes for possible genetic penetrance in BC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28315507     DOI: 10.5301/ijbm.5000258

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  7 in total

1.  RAD51 paralogs promote genomic integrity and chemoresistance in cancer by facilitating homologous recombination.

Authors:  Janelle Louise Harris; Andrea Rabellino; Kum Kum Khanna
Journal:  Ann Transl Med       Date:  2018-12

2.  Data on Single Nucleotide Polymorphism of DNA Repair Genes and Breast Cancer Risk from Poland.

Authors:  Beata Smolarz; Magdalena Bryś; Ewa Forma; Marek Zadrożny; Jan Bieńkiewicz; Hanna Romanowicz
Journal:  Pathol Oncol Res       Date:  2017-12-05       Impact factor: 3.201

3.  Polymorphism of XRCC3 in Egyptian Breast Cancer Patients.

Authors:  Mona Khyri Alkasaby; Abeer Ibrahim Abd El-Fattah; Iman Hassan Ibrahim; Hesham Samir Abd El-Samie
Journal:  Pharmgenomics Pers Med       Date:  2020-08-06

4.  Comprehensive Analysis of the Expression and Prognosis for RAD51 Family in Human Breast Cancer.

Authors:  Yaqin Shi; Meng Shen; Mengdan Xu; Min Tao; Kai Chen; Qingqing Zhu
Journal:  Int J Gen Med       Date:  2022-05-13

5.  Association of GSTP1 p.Ile105Val (rs1695, c.313A > G) Variant with the Risk of Breast Carcinoma among Egyptian Women.

Authors:  Magdy M Youssef; Afaf M Elsaid; Rasha A El-Saeed; Riyadh T Mukhlif; Hisham Megahed; Adel I Al-Alawy; Rami M Elshazli
Journal:  Biochem Genet       Date:  2021-05-03       Impact factor: 1.890

6.  The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case-control studies.

Authors:  Weiqing Liu; Shumin Ma; Lei Liang; Zhiyong Kou; Hongbin Zhang; Jun Yang
Journal:  BMC Med Genomics       Date:  2021-04-30       Impact factor: 3.063

7.  DNA Repair Mechanism Gene, XRCC1A ( Arg194Trp) but not XRCC3 ( Thr241Met) Polymorphism Increased the Risk of Breast Cancer in Premenopausal Females: A Case-Control Study in Northeastern Region of India.

Authors:  K Rekha Devi; Jishan Ahmed; Kanwar Narain; Kaustab Mukherjee; Gautam Majumdar; Saia Chenkual; Jason C Zonunmawia
Journal:  Technol Cancer Res Treat       Date:  2017-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.